How FMI’s Survey Helped a Large Pharmaceutical Company Enhance its Drug Pipeline Management
Healthcare, Pharmaceuticals and Medical devices
A leading pharmaceutical company wanted to scale higher in the intensely competitive market for oncology drugs, to capitalize on multibillion dollar opportunities in the market. The client mainly engages in the research & development, manufacturing, and marketing of new drug delivery methods in the oncology drugs market. However, the client was struggling with ensuring compliance to stringent regulations and strict certification processes laid down by governing bodies, which ultimately restricted its growth in the oncology drugs market. The client needed intelligence for improving the efficiency of its business operations and phases of its drug pipeline to improve the prospects of growth and expand in the oncology drugs market. The company also wanted to establish a strong presence in various geographical markets for oncology drugs, and sought insights for making better decisions for improving its pipeline management system.
FMI’s study on the oncology drugs market predicts that, the demand for small molecule-based oncology drugs is likely to grow rapidly in the coming years. The increasing prevalence of cancer is triggering burgeoning demand for effective oncology drugs, and thereby, opening new avenues of growth for pharmaceutical companies. However, with the growing potential for oncology drugs, the competition in the market has increased significantly in the past few years. In addition, strict certification processes and stringent regulations have been influencing the manufacturing strategies of players in the oncology drugs market. Rejections at these certification processes have created significant challenges for pharmaceutical companies in the oncology drugs market. Nevertheless, the rapidly growing healthcare sector in developing regions, along with the increasing growth of medical tourism in emerging economies, is likely to create lucrative opportunities. FMI projects that, stakeholders in the oncology drugs market will soon turn to developing countries such as China and India to capitalize on the increasing demand for more efficient oncology drugs, in the coming years.
Based on its thorough research on the oncology drugs market, FMI provided the client with detailed qualitative as well as quantitative insights on how to scale up in this highly competitive market. FMI could help the client with in-depth information on factors that are impacting the development of small molecule-based oncology drugs. FMI also assessed the factors instrumental in enhancing the efficiency of molecule pipeline management, which could lead to cost savings and help the client improve the efficacy of oncology drugs. FMI helped the client with detailed analysis on the recent regulatory changes that have impacted the potential for oncology drugs, which could be an important part of the client’s upcoming business strategies.
With the help of FMI’s predictions on regional growth prospects in oncology drugs market, and detailed analysis on the competitive landscape of the market, the client could plan its regional strategies more precisely. The company could streamline its pipeline management strategies, which led to significant cost savings in oncology drug manufacturing. FMI’s extensive research on the changing regulatory environment in the oncology drugs market also helped the client avoid rejections in the last stages of production. Also, the client could set new pricing benchmarks of new molecule-based drugs to capture more opportunities in the global as well as regional markets.